An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Trial Profile

An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Nivolumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Ipilimumab; Paclitaxel; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate 227
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 16 Apr 2018 According to the Bristol-Myers Squibb media release, data from this trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2018.
    • 16 Apr 2018 Results published in the Bristol-Myers Squibb Media Release
    • 16 Apr 2018 Results assessing progression-free survival with nivolumab plus ipilimumab versus chemotherapy among patients with a high tumor mutational burden , were published in the New England Journal of Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top